1.4M XNAS Volume
XNAS 21 Mar, 2025 5:30 PM (EDT)
| Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|
| Paul B. Bolno | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.48 per share. | 07 Mar 2025 | 169,025 | 507,376 (1%) | 0% | 2.5 | 419,182 | Ordinary Shares |
| Paul B. Bolno | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Mar 2025 | 48,059 | 0 | - | - | Share Option (right to buy) | |
| Paul B. Bolno | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Mar 2025 | 120,966 | 0 | - | - | Share Option (right to buy) | |
| Paul B. Bolno | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 9.57 per share. | 07 Mar 2025 | 169,025 | 338,351 (0%) | 0% | 9.6 | 1,617,569 | Ordinary Shares |
| Gregory L. Verdine | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.48 per share. | 05 Mar 2025 | 133,402 | 312,517 (0%) | 0% | 2.5 | 330,837 | Ordinary Shares |
| Gregory L. Verdine | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Mar 2025 | 133,402 | 0 | - | - | Share Option (right to buy) | |
| Gregory L. Verdine | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Mar 2025 | 133,000 | 133,402 | - | - | Share Option (right to buy) | |
| Gregory L. Verdine | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.48 per share. | 05 Mar 2025 | 133,000 | 179,155 (0%) | 0% | 2.5 | 329,840 | Ordinary Shares |
| Chandra Vargeese | See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.48 per share. | 04 Mar 2025 | 91,754 | 362,687 (1%) | 0% | 2.5 | 227,550 | Ordinary Shares |
| Chandra Vargeese | See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Mar 2025 | 75,332 | 0 | - | - | Share Option (right to buy) | |
| Chandra Vargeese | See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Mar 2025 | 16,422 | 0 | - | - | Share Option (right to buy) | |
| Paul B. Bolno | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Feb 2025 | 121,000 | 338,351 (0%) | 0% | 0 | Ordinary Shares | |
| Paul B. Bolno | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Feb 2025 | 1,000,000 | 1,000,000 | - | - | Share Option (right to buy) | |
| Christopher Francis | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Feb 2025 | 151,000 | 151,000 | - | - | Share Option (right to buy) | |
| Christopher Francis | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Feb 2025 | 25,000 | 25,000 (0%) | 0% | 0 | Ordinary Shares | |
| Kyle Moran | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Feb 2025 | 42,000 | 89,218 (0%) | 0% | 0 | Ordinary Shares | |
| Kyle Moran | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Feb 2025 | 252,000 | 252,000 | - | - | Share Option (right to buy) | |
| Chandra Vargeese | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Feb 2025 | 37,000 | 270,933 (0%) | 0% | 0 | Ordinary Shares | |
| Chandra Vargeese | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Feb 2025 | 224,000 | 224,000 | - | - | Share Option (right to buy) | |
| Chandra Vargeese | See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.48 per share. | 23 Jan 2025 | 46,000 | 233,933 (0%) | 0% | 2.5 | 114,080 | Ordinary Shares |
| Chandra Vargeese | See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Jan 2025 | 46,000 | 16,422 | - | - | Share Option (right to buy) | |
| Bolno B. Paul | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Nov 2024 | 50,000 | 47,778 | - | - | Share Option (right to buy) | |
| B. Paul Bolno | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 15.00 per share. | 25 Nov 2024 | 50,000 | 217,351 (0%) | 0% | 15 | 750,000 | Ordinary Shares |
| Bolno Paul B. | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.48 per share. | 25 Nov 2024 | 50,000 | 267,351 (0%) | 0% | 2.5 | 124,000 | Ordinary Shares |
| Paul B. Bolno | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 14.32 per share. | 15 Nov 2024 | 51,234 | 217,351 (0%) | 0% | 14.3 | 733,671 | Ordinary Shares |
| Christopher Francis | See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.17 per share. | 08 Nov 2024 | 36,000 | 36,000 (0%) | 0% | 8.2 | 294,120 | Ordinary Shares |
| Christopher Francis | See Remarks | Sale of securities on an exchange or to another person at price $ 16.00 per share. | 08 Nov 2024 | 36,000 | 0 (0%) | 0% | 16 | 576,000 | Ordinary Shares |
| Christopher Francis | See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Nov 2024 | 36,000 | 0 | - | - | Share Option (right to buy) | |
| Paul B. Bolno | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 15.00 per share. | 16 Oct 2024 | 90,474 | 268,585 (0%) | 0% | 15 | 1,357,110 | Ordinary Shares |
| Christopher Francis | See Remarks | Sale of securities on an exchange or to another person at price $ 13.00 per share. | 16 Oct 2024 | 40,997 | 0 (0%) | 0% | 13 | 532,961 | Ordinary Shares |
| Christopher Francis | See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Oct 2024 | 65,625 | 84,375 | - | - | Share Option (right to buy) | |
| Christopher Francis | See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Oct 2024 | 40,997 | 0 | - | - | Share Option (right to buy) | |
| Christopher Francis | See Remarks | Sale of securities on an exchange or to another person at price $ 13.50 per share. | 16 Oct 2024 | 22,500 | 0 (0%) | 0% | 13.5 | 303,750 | Ordinary Shares |
| Christopher Francis | See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.83 per share. | 16 Oct 2024 | 22,500 | 22,500 (0%) | 0% | 2.8 | 63,675 | Ordinary Shares |
| Christopher Francis | See Remarks | Sale of securities on an exchange or to another person at price $ 13.75 per share. | 16 Oct 2024 | 65,625 | 0 (0%) | 0% | 13.8 | 902,344 | Ordinary Shares |
| Christopher Francis | See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.48 per share. | 16 Oct 2024 | 40,997 | 40,997 (0%) | 0% | 2.5 | 101,673 | Ordinary Shares |
| Christopher Francis | See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Oct 2024 | 22,500 | 22,500 | - | - | Share Option (right to buy) | |
| Christopher Francis | See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.14 per share. | 16 Oct 2024 | 65,625 | 65,625 (0%) | 0% | 3.1 | 206,063 | Ordinary Shares |
| Christopher Francis | See Remarks | Sale of securities on an exchange or to another person at price $ 14.00 per share. | 16 Oct 2024 | 79,714 | 0 (0%) | 0% | 14 | 1,115,996 | Ordinary Shares |
| Kyle Moran | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Oct 2024 | 25,000 | 0 | - | - | Share Option (right to buy) | |
| Kyle Moran | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.48 per share. | 11 Oct 2024 | 25,000 | 44,777 (0%) | 0% | 2.5 | 62,000 | Ordinary Shares |
| Kyle Moran | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 9.00 per share. | 25 Sep 2024 | 17,146 | 19,777 (0%) | 0% | 9 | 154,314 | Ordinary Shares |
| Paul B. Bolno | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 5.78 per share. | 21 Aug 2024 | 48,366 | 359,059 (1%) | 0% | 5.8 | 279,555 | Ordinary Shares |
| Christian O. Henry | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Aug 2024 | 32,230 | 32,230 | - | - | Share Option (right to buy) | |
| Christian O. Henry | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Aug 2024 | 16,115 | 16,115 (0%) | 0% | 0 | Ordinary Shares | |
| Mark H.N. Corrigan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Aug 2024 | 32,230 | 32,230 (0%) | 0% | 0 | Ordinary Shares | |
| Mark H.N. Corrigan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Aug 2024 | 64,460 | 64,460 | - | - | Share Option (right to buy) | |
| Adrian Rawcliffe | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Aug 2024 | 32,230 | 32,230 | - | - | Share Option (right to buy) | |
| Adrian Rawcliffe | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Aug 2024 | 16,115 | 16,115 (0%) | 0% | 0 | Ordinary Shares | |
| Gregory L. Verdine | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Aug 2024 | 16,115 | 46,115 (0%) | 0% | 0 | Ordinary Shares | |
| Gregory L. Verdine | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Aug 2024 | 32,230 | 32,230 | - | - | Share Option (right to buy) | |
| Heidi L. Wagner | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Aug 2024 | 32,230 | 32,230 (0%) | 0% | 0 | Ordinary Shares | |
| Heidi L. Wagner | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Aug 2024 | 64,460 | 64,460 | - | - | Share Option (right to buy) | |
| Ken Takanashi | Director, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Aug 2024 | 32,230 | 32,230 | - | - | Share Option (right to buy) | |
| Ken Takanashi | Director, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Aug 2024 | 16,115 | 5,721,175 (16%) | 0% | 0 | Ordinary Shares | |
| Aik Na Tan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Aug 2024 | 16,115 | 16,115 (0%) | 0% | 0 | Ordinary Shares | |
| Aik Na Tan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Aug 2024 | 32,230 | 32,230 | - | - | Share Option (right to buy) | |
| Chandra Vargeese | See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Jul 2024 | 68,210 | 75,332 | - | - | Share Option (right to buy) | |
| Chandra Vargeese | See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.48 per share. | 22 Jul 2024 | 68,210 | 185,061 (0%) | 0% | 2.5 | 169,161 | Ordinary Shares |
| Kyle Moran | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 6.17 per share. | 03 Apr 2024 | 15,630 | 33,921 (0%) | 0% | 6.2 | 96,421 | Ordinary Shares |
| Moran Kyle | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Feb 2024 | 371,500 | 371,500 | - | - | Share Option (right to buy) | |
| Bolno B. Paul | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Feb 2024 | 1,008,600 | 1,008,600 | - | - | Share Option (right to buy) | |
| Francis Christopher | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Feb 2024 | 286,400 | 286,400 | - | - | Share Option (right to buy) | |
| Vargeese Chandra | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Feb 2024 | 361,700 | 361,700 | - | - | Share Option (right to buy) | |
| Kyle Moran | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 4.75 per share. | 23 Aug 2023 | 37,062 | 46,120 (0%) | 0% | 4.8 | 176,119 | Ordinary Shares |
| Christian O. Henry | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Aug 2023 | 45,000 | 45,000 | - | - | Share Option (right to buy) | |
| Mark H.N. Corrigan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Aug 2023 | 45,000 | 45,000 | - | - | Share Option (right to buy) | |
| Adrian Rawcliffe | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Aug 2023 | 45,000 | 45,000 | - | - | Share Option (right to buy) | |
| Gregory L. Verdine | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Aug 2023 | 45,000 | 45,000 | - | - | Share Option (right to buy) | |
| Heidi L. Wagner | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Aug 2023 | 45,000 | 45,000 | - | - | Share Option (right to buy) | |
| Ken Takanashi | Director, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Aug 2023 | 45,000 | 45,000 | - | - | Share Option (right to buy) | |
| Aik Na Tan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Aug 2023 | 45,000 | 45,000 | - | - | Share Option (right to buy) | |
| Paul B. Bolno | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Feb 2023 | 771,000 | 771,000 | - | - | Share Option (right to buy) | |
| Paul B. Bolno | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 4.04 per share. | 16 Feb 2023 | 29,400 | 407,425 (1%) | 0% | 4.0 | 118,776 | Ordinary Shares |
| Christopher Francis | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Feb 2023 | 244,700 | 244,700 | - | - | Share Option (right to buy) | |
| Christopher Francis | See Remarks | Sale of securities on an exchange or to another person at price $ 4.03 per share. | 16 Feb 2023 | 10,258 | 79,714 (0%) | 0% | 4.0 | 41,340 | Ordinary Shares |
| Kyle Moran | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Feb 2023 | 272,700 | 272,700 | - | - | Share Option (right to buy) | |
| Kyle Moran | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 4.04 per share. | 16 Feb 2023 | 9,729 | 79,751 (0%) | 0% | 4.0 | 39,305 | Ordinary Shares |
| Chandra Vargeese | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Feb 2023 | 295,400 | 295,400 | - | - | Share Option (right to buy) | |
| Chandra Vargeese | See Remarks | Sale of securities on an exchange or to another person at price $ 4.03 per share. | 16 Feb 2023 | 10,249 | 106,624 (0%) | 0% | 4.0 | 41,303 | Ordinary Shares |
| Christian O. Henry | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Aug 2022 | 21,000 | 21,000 | - | - | Share Option (right to buy) | |
| Mark H.N. Corrigan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Aug 2022 | 21,000 | 21,000 | - | - | Share Option (right to buy) | |
| Adrian Rawcliffe | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Aug 2022 | 21,000 | 21,000 | - | - | Share Option (right to buy) | |
| Gregory L. Verdine | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Aug 2022 | 21,000 | 21,000 | - | - | Share Option (right to buy) | |
| Heidi L. Wagner | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Aug 2022 | 21,000 | 21,000 | - | - | Share Option (right to buy) | |
| Ken Takanashi | Director, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Aug 2022 | 21,000 | 21,000 | - | - | Share Option (right to buy) | |
| Aik Na Tan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Aug 2022 | 21,000 | 21,000 | - | - | Share Option (right to buy) | |
| Paul B. Bolno | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Jul 2022 | 180,000 | 180,000 | - | - | Share Option (right to buy) | |
| Christopher Francis | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Jul 2022 | 45,000 | 45,000 | - | - | Share Option (right to buy) | |
| Kyle Moran | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Jul 2022 | 60,000 | 60,000 | - | - | Share Option (right to buy) | |
| Chandra Vargeese | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Jul 2022 | 60,000 | 60,000 | - | - | Share Option (right to buy) | |
| Michael A. Panzara | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Jul 2022 | 60,000 | 60,000 | - | - | Share Option (right to buy) | |
| Paul B. Bolno | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 1.72 per share. | 04 May 2022 | 33,501 | 436,825 (1%) | 0% | 1.7 | 57,622 | Ordinary Shares |
| Paul B. Bolno | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 May 2022 | 92,500 | 470,326 (1%) | 0% | 0 | Ordinary Shares | |
| Christopher Francis | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 May 2022 | 32,500 | 100,839 (0%) | 0% | 0 | Ordinary Shares | |
| Christopher Francis | See Remarks | Sale of securities on an exchange or to another person at price $ 1.72 per share. | 04 May 2022 | 10,867 | 89,972 (0%) | 0% | 1.7 | 18,691 | Ordinary Shares |
| Kyle Moran | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 1.72 per share. | 04 May 2022 | 5,021 | 84,567 (0%) | 0% | 1.7 | 8,636 | Ordinary Shares |
| Kyle Moran | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 May 2022 | 15,000 | 89,588 (0%) | 0% | 0 | Ordinary Shares | |
| Michael A. Panzara | See Remarks | Sale of securities on an exchange or to another person at price $ 1.72 per share. | 04 May 2022 | 16,714 | 109,103 (0%) | 0% | 1.7 | 28,748 | Ordinary Shares |
| Michael A. Panzara | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 May 2022 | 50,000 | 125,817 (0%) | 0% | 0 | Ordinary Shares | |
| Paul B. Bolno | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 2.32 per share. | 16 Feb 2022 | 33,150 | 377,826 (1%) | 0% | 2.3 | 76,908 | Ordinary Shares |
| Christopher Francis | See Remarks | Sale of securities on an exchange or to another person at price $ 2.31 per share. | 16 Feb 2022 | 10,123 | 68,339 (0%) | 0% | 2.3 | 23,384 | Ordinary Shares |
| Kyle Moran | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 2.31 per share. | 16 Feb 2022 | 9,204 | 74,588 (0%) | 0% | 2.3 | 21,261 | Ordinary Shares |
| Chandra Vargeese | Chief Technology Officer | Sale of securities on an exchange or to another person at price $ 2.32 per share. | 16 Feb 2022 | 10,603 | 77,809 (0%) | 0% | 2.3 | 24,599 | Ordinary Shares |
| Michael A. Panzara | See Remarks | Sale of securities on an exchange or to another person at price $ 2.31 per share. | 16 Feb 2022 | 10,603 | 75,817 (0%) | 0% | 2.3 | 24,493 | Ordinary Shares |
| Paul B. Bolno | Director, See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jan 2022 | 600,000 | 600,000 | - | - | Share Option (right to buy) | |
| Christopher Francis | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jan 2022 | 150,000 | 150,000 | - | - | Share Option (right to buy) | |
| Kyle Moran | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jan 2022 | 175,000 | 175,000 | - | - | Share Option (right to buy) | |
| Chandra Vargeese | Chief Technology Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jan 2022 | 200,000 | 200,000 | - | - | Share Option (right to buy) | |
| Michael A. Panzara | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jan 2022 | 200,000 | 200,000 | - | - | Share Option (right to buy) | |
| Christian O. Henry | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Aug 2021 | 42,000 | 42,000 | - | - | Share Option (right to buy) | |
| Mark H.N. Corrigan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Aug 2021 | 21,000 | 21,000 | - | - | Share Option (right to buy) | |
| Adrian Rawcliffe | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Aug 2021 | 42,000 | 42,000 | - | - | Share Option (right to buy) | |
| Gregory L. Verdine | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Aug 2021 | 42,000 | 42,000 | - | - | Share Option (right to buy) | |
| Heidi L. Wagner | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Aug 2021 | 21,000 | 21,000 | - | - | Share Option (right to buy) | |
| Ken Takanashi | Director, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Aug 2021 | 42,000 | 42,000 | - | - | Share Option (right to buy) | |
| Aik Na Tan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Aug 2021 | 21,000 | 21,000 | - | - | Share Option (right to buy) | |
| Kyle Moran | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.48 per share. | 24 Mar 2021 | 10,930 | 80,792 (0%) | 0% | 2.5 | 27,106 | Ordinary Shares |
| Kyle Moran | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 24 Mar 2021 | 10,930 | 25,000 | - | - | Share Option (right to buy) | |
| Paul B. Bolno | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2021 | 150,000 | 422,181 (1%) | 0% | 0 | Ordinary Shares | |
| Paul B. Bolno | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 10.57 per share. | 01 Feb 2021 | 11,205 | 410,976 (1%) | 0% | 10.6 | 118,437 | Ordinary Shares |
| Paul B. Bolno | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2021 | 200,000 | 200,000 | - | - | Share Option (right to buy) | |
| Christopher Francis | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2021 | 50,000 | 81,160 (0%) | 0% | 0 | Ordinary Shares | |
| Christopher Francis | See Remarks | Sale of securities on an exchange or to another person at price $ 10.57 per share. | 01 Feb 2021 | 2,698 | 78,462 (0%) | 0% | 10.6 | 28,518 | Ordinary Shares |
| Christopher Francis | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2021 | 50,000 | 50,000 | - | - | Share Option (right to buy) | |
| Kyle Moran | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2021 | 50,000 | 71,584 (0%) | 0% | 0 | Ordinary Shares | |
| Kyle Moran | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2021 | 50,000 | 50,000 | - | - | Share Option (right to buy) | |
| Kyle Moran | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 10.57 per share. | 01 Feb 2021 | 1,722 | 69,862 (0%) | 0% | 10.6 | 18,202 | Ordinary Shares |
| Chandra Vargeese | Chief Technology Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2021 | 50,000 | 50,000 | - | - | Share Option (right to buy) | |
| Chandra Vargeese | Chief Technology Officer | Sale of securities on an exchange or to another person at price $ 10.57 per share. | 01 Feb 2021 | 3,145 | 85,412 (0%) | 0% | 10.6 | 33,243 | Ordinary Shares |
| Chandra Vargeese | Chief Technology Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2021 | 50,000 | 88,557 (0%) | 0% | 0 | Ordinary Shares | |
| Michael Panzara | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2021 | 50,000 | 89,349 (0%) | 0% | 0 | Ordinary Shares | |
| Michael Panzara | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2021 | 50,000 | 50,000 | - | - | Share Option (right to buy) | |
| Michael Panzara | See Remarks | Sale of securities on an exchange or to another person at price $ 10.57 per share. | 01 Feb 2021 | 2,929 | 86,420 (0%) | 0% | 10.6 | 30,960 | Ordinary Shares |
| Paul B. Bolno | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 15.00 per share. | 15 Sep 2020 | 100,000 | 272,181 (0%) | 0% | 15 | 1,500,000 | Ordinary Shares |
| Paul B. Bolno | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Sep 2020 | 100,000 | 97,778 | - | - | Share Option (right to buy) | |
| Paul B. Bolno | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.48 per share. | 15 Sep 2020 | 100,000 | 372,181 (1%) | 0% | 2.5 | 248,000 | Ordinary Shares |
| Paul B. Bolno | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 12.00 per share. | 25 Aug 2020 | 25,000 | 272,181 (0%) | 0% | 12 | 300,000 | Ordinary Shares |
| Paul B. Bolno | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Aug 2020 | 25,000 | 197,778 | - | - | Share Option (right to buy) | |
| Paul B. Bolno | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.48 per share. | 25 Aug 2020 | 25,000 | 297,181 (0%) | 0% | 2.5 | 62,000 | Ordinary Shares |
| Christian O. Henry | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Aug 2020 | 10,500 | 10,500 | - | - | Share Option (right to buy) | |
| Mark H.N. Corrigan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Aug 2020 | 10,500 | 10,500 | - | - | Share Option (right to buy) | |
| Adrian Rawcliffe | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Aug 2020 | 10,500 | 10,500 | - | - | Share Option (right to buy) | |
| Gregory L. Verdine | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Aug 2020 | 10,500 | 10,500 | - | - | Share Option (right to buy) | |
| Peter Kolchinsky | Director, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Aug 2020 | 10,500 | 10,500 | - | - | Share Option (right to buy) | |
| Heidi L. Wagner | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Aug 2020 | 10,500 | 10,500 | - | - | Share Option (right to buy) | |
| Ken Takanashi | Director, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Aug 2020 | 10,500 | 10,500 | - | - | Share Option (right to buy) | |
| Amy Pott | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Aug 2020 | 10,500 | 10,500 | - | - | Share Option (right to buy) | |
| Aik Na Tan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Aug 2020 | 21,000 | 21,000 | - | - | Share Option (right to buy) | |
| Paul B. Bolno | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 10.82 per share. | 02 Jul 2020 | 4,509 | 315,249 (0%) | 0% | 10.8 | 48,787 | Ordinary Shares |
| Paul B. Bolno | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Jul 2020 | 100,000 | 222,778 | - | - | Share Option (right to buy) | |
| Paul B. Bolno | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 10.27 per share. | 02 Jul 2020 | 95,921 | 272,181 (0%) | 0% | 10.3 | 985,109 | Ordinary Shares |
| Paul B. Bolno | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 10.91 per share. | 02 Jul 2020 | 4,079 | 368,102 (1%) | 0% | 10.9 | 44,502 | Ordinary Shares |
| Paul B. Bolno | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.48 per share. | 02 Jul 2020 | 100,000 | 372,181 (1%) | 0% | 2.5 | 248,000 | Ordinary Shares |
| Paul B. Bolno | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 10.26 per share. | 02 Jul 2020 | 43,068 | 272,181 (0%) | 0% | 10.3 | 441,878 | Ordinary Shares |
| Paul B. Bolno | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Mar 2020 | 63,000 | 63,000 | - | - | Share Option (right to buy) | |
| Christopher Francis | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Mar 2020 | 36,000 | 36,000 | - | - | Share Option (right to buy) | |
| Chandra Vargeese | Senior VP, Drug Discovery | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Mar 2020 | 36,000 | 36,000 | - | - | Share Option (right to buy) | |
| Michael Panzara | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Mar 2020 | 36,000 | 36,000 | - | - | Share Option (right to buy) | |
| David Gaiero | Interim CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Mar 2020 | 18,000 | 18,000 | - | - | Share Option (right to buy) | |
| Paul B. Bolno | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 7.85 per share. | 18 Feb 2020 | 11,451 | 319,758 (0%) | 0% | 7.8 | 89,890 | Ordinary Shares |
| Christopher Francis | See Remarks | Sale of securities on an exchange or to another person at price $ 7.85 per share. | 18 Feb 2020 | 2,708 | 31,160 (0%) | 0% | 7.9 | 21,258 | Ordinary Shares |
| Chandra Vargeese | Senior VP, Drug Discovery | Sale of securities on an exchange or to another person at price $ 7.85 per share. | 18 Feb 2020 | 3,188 | 37,057 (0%) | 0% | 7.9 | 25,026 | Ordinary Shares |
| Michael Panzara | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 7.85 per share. | 18 Feb 2020 | 2,981 | 39,349 (0%) | 0% | 7.9 | 23,401 | Ordinary Shares |
| Chandra Vargeese | Senior VP, Drug Discovery | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Dec 2019 | 6,000 | 143,542 | - | - | Share Option (right to buy) | |
| Chandra Vargeese | Senior VP, Drug Discovery | Sale of securities on an exchange or to another person at price $ 35.00 per share. | 03 Dec 2019 | 6,000 | 40,245 (0%) | 0% | 35 | 210,000 | Ordinary Shares |
| Chandra Vargeese | Senior VP, Drug Discovery | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.48 per share. | 03 Dec 2019 | 6,000 | 46,245 (0%) | 0% | 2.5 | 14,880 | Ordinary Shares |
| Gregory L. Verdine | None | Sale of securities on an exchange or to another person at price $ 30.27 per share. | 20 Nov 2019 | 24,030 | 36,009 (0%) | 0% | 30.3 | 727,388 | Ordinary Shares |
| Gregory L. Verdine | None | Sale of securities on an exchange or to another person at price $ 32.74 per share. | 20 Nov 2019 | 2,609 | 30,000 (0%) | 0% | 32.7 | 85,419 | Ordinary Shares |
| Gregory L. Verdine | None | Sale of securities on an exchange or to another person at price $ 31.59 per share. | 20 Nov 2019 | 3,400 | 32,609 (0%) | 0% | 31.6 | 107,406 | Ordinary Shares |
| Mark H.N. Corrigan | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Sep 2019 | 21,000 | 21,000 | - | - | Share Option (right to buy) | |
| Heidi L. Wagner | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Sep 2019 | 21,000 | 21,000 | - | - | Share Option (right to buy) | |
| Amy Pott | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Sep 2019 | 21,000 | 21,000 | - | - | Share Option (right to buy) | |
| Christian O. Henry | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Aug 2019 | 10,500 | 10,500 | - | - | Share Option (right to buy) | |
| Adrian Rawcliffe | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Aug 2019 | 10,500 | 10,500 | - | - | Share Option (right to buy) | |
| Gregory L. Verdine | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Aug 2019 | 10,500 | 10,500 | - | - | Share Option (right to buy) | |
| Peter Kolchinsky | Director, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Aug 2019 | 10,500 | 10,500 | - | - | Share Option (right to buy) | |
| Koji Miura | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Aug 2019 | 10,500 | 10,500 | - | - | Share Option (right to buy) | |
| Ken Takanashi | Director, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Aug 2019 | 10,500 | 10,500 | - | - | Share Option (right to buy) | |
| Michael Panzara | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 27.26 per share. | 05 Jul 2019 | 445 | 42,330 (0%) | 0% | 27.3 | 12,131 | Ordinary Shares |
| Michael Panzara | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 26.88 per share. | 05 Jul 2019 | 2,613 | 42,775 (0%) | 0% | 26.9 | 70,237 | Ordinary Shares |
| Paul B. Bolno | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 45.22 per share. | 15 Mar 2019 | 8,237 | 332,972 (0%) | 0% | 45.2 | 372,477 | Ordinary Shares |
| Paul B. Bolno | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Mar 2019 | 50,000 | 322,778 | - | - | Share Option (right to buy) | |
| Paul B. Bolno | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 46.00 per share. | 15 Mar 2019 | 1,763 | 331,209 (0%) | 0% | 46 | 81,098 | Ordinary Shares |
| Paul B. Bolno | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.48 per share. | 15 Mar 2019 | 50,000 | 381,209 (1%) | 0% | 2.5 | 124,000 | Ordinary Shares |
| Paul B. Bolno | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 45.89 per share. | 15 Mar 2019 | 5,065 | 341,209 (0%) | 0% | 45.9 | 232,433 | Ordinary Shares |
| Paul B. Bolno | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 45.45 per share. | 15 Mar 2019 | 34,935 | 346,274 (1%) | 0% | 45.5 | 1,587,796 | Ordinary Shares |
| Paul B. Bolno | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Mar 2019 | 60,000 | 331,209 (0%) | 0% | 0 | Ordinary Shares | |
| Christopher Francis | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Mar 2019 | 13,500 | 33,868 (0%) | 0% | 0 | Ordinary Shares | |
| Chandra Vargeese | Senior VP, Drug Discovery | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Mar 2019 | 15,000 | 40,245 (0%) | 0% | 0 | Ordinary Shares | |
| Michael Panzara | Franchise Lead, Neurology | Sale of securities on an exchange or to another person at price $ 48.00 per share. | 07 Mar 2019 | 7,000 | 45,388 (0%) | 0% | 48 | 336,000 | Ordinary Shares |
| Michael Panzara | Franchise Lead, Neurology | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Mar 2019 | 15,000 | 52,388 (0%) | 0% | 0 | Ordinary Shares | |
| Keith Regnante | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Mar 2019 | 13,500 | 29,186 (0%) | 0% | 0 | Ordinary Shares | |
| Paul B. Bolno | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 36.38 per share. | 19 Feb 2019 | 7,614 | 271,328 (0%) | 0% | 36.4 | 276,997 | Ordinary Shares |
| Paul B. Bolno | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 37.46 per share. | 19 Feb 2019 | 119 | 271,209 (0%) | 0% | 37.5 | 4,458 | Ordinary Shares |
| Christopher Francis | See Remarks | Sale of securities on an exchange or to another person at price $ 36.84 per share. | 19 Feb 2019 | 1,709 | 20,368 (0%) | 0% | 36.8 | 62,959 | Ordinary Shares |
| Chandra Vargeese | Senior VP, Drug Discovery | Sale of securities on an exchange or to another person at price $ 36.84 per share. | 19 Feb 2019 | 2,055 | 25,245 (0%) | 0% | 36.8 | 75,706 | Ordinary Shares |
| Michael Panzara | Franchise Lead, Neurology | Sale of securities on an exchange or to another person at price $ 36.84 per share. | 19 Feb 2019 | 1,837 | 37,388 (0%) | 0% | 36.8 | 67,674 | Ordinary Shares |
| Keith Regnante | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 36.84 per share. | 19 Feb 2019 | 1,298 | 15,686 (0%) | 0% | 36.8 | 47,818 | Ordinary Shares |
| Gregory L. Verdine | None | Sale of securities on an exchange or to another person at price $ 38.59 per share. | 14 Nov 2018 | 10,700 | 64,339 (0%) | 0% | 38.6 | 412,913 | Ordinary Shares |
| Gregory L. Verdine | None | Sale of securities on an exchange or to another person at price $ 39.52 per share. | 14 Nov 2018 | 4,300 | 60,039 (0%) | 0% | 39.5 | 169,936 | Ordinary Shares |
| Christopher Francis | See Remarks | Sale of securities on an exchange or to another person at price $ 56.00 per share. | 24 Sep 2018 | 1,032 | 22,077 (0%) | 0% | 56 | 57,792 | Ordinary Shares |
| Christopher Francis | See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 24 Sep 2018 | 1,032 | 51,540 | - | - | Share Option (right to buy) | |
| Christopher Francis | See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.48 per share. | 24 Sep 2018 | 10,543 | 32,620 (0%) | 0% | 2.5 | 26,147 | Ordinary Shares |
| Christopher Francis | See Remarks | Sale of securities on an exchange or to another person at price $ 56.00 per share. | 24 Sep 2018 | 10,543 | 22,077 (0%) | 0% | 56 | 590,408 | Ordinary Shares |
| Christopher Francis | See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 24 Sep 2018 | 10,543 | 40,997 | - | - | Share Option (right to buy) | |
| Christopher Francis | See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.48 per share. | 24 Sep 2018 | 1,032 | 23,109 (0%) | 0% | 2.5 | 2,559 | Ordinary Shares |
| Chandra Vargeese | Senior VP, Drug Discovery | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 24 Sep 2018 | 3,000 | 149,542 | - | - | Share Option (right to buy) | |
| Chandra Vargeese | Senior VP, Drug Discovery | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.48 per share. | 24 Sep 2018 | 3,000 | 30,300 (0%) | 0% | 2.5 | 7,440 | Ordinary Shares |
| Chandra Vargeese | Senior VP, Drug Discovery | Sale of securities on an exchange or to another person at price $ 55.00 per share. | 24 Sep 2018 | 3,000 | 27,300 (0%) | 0% | 55 | 165,000 | Ordinary Shares |
| Keith Regnante | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 24 Sep 2018 | 29,500 | 90,500 | - | - | Share Option (right to buy) | |
| Keith Regnante | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 55.00 per share. | 24 Sep 2018 | 29,500 | 16,984 (0%) | 0% | 55 | 1,622,500 | Ordinary Shares |
| Keith Regnante | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 20.89 per share. | 24 Sep 2018 | 29,500 | 46,484 (0%) | 0% | 20.9 | 616,255 | Ordinary Shares |
| Christian O. Henry | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Aug 2018 | 9,000 | 9,000 | - | - | Share Option (right to buy) | |
| Adrian Rawcliffe | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Aug 2018 | 9,000 | 9,000 | - | - | Share Option (right to buy) | |
| Gregory L. Verdine | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Aug 2018 | 9,000 | 9,000 | - | - | Share Option (right to buy) | |
| Peter Kolchinsky | Director, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Aug 2018 | 9,000 | 9,000 | - | - | Share Option (right to buy) | |
| Koji Miura | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Aug 2018 | 9,000 | 9,000 | - | - | Share Option (right to buy) | |
| Ken Takanashi | Director, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Aug 2018 | 9,000 | 9,000 | - | - | Share Option (right to buy) | |
| Christopher Francis | See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Jul 2018 | 24,496 | 52,572 | - | - | Share Option (right to buy) | |
| Christopher Francis | See Remarks | Sale of securities on an exchange or to another person at price $ 38.22 per share. | 09 Jul 2018 | 596 | 22,077 (0%) | 0% | 38.2 | 22,779 | Ordinary Shares |
| Christopher Francis | See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.48 per share. | 09 Jul 2018 | 596 | 22,673 (0%) | 0% | 2.5 | 1,478 | Ordinary Shares |
| Christopher Francis | See Remarks | Sale of securities on an exchange or to another person at price $ 37.25 per share. | 09 Jul 2018 | 23,900 | 22,077 (0%) | 0% | 37.3 | 890,275 | Ordinary Shares |
| Christopher Francis | See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.48 per share. | 09 Jul 2018 | 23,900 | 45,977 (0%) | 0% | 2.5 | 59,272 | Ordinary Shares |
| Christopher Francis | See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.48 per share. | 30 May 2018 | 24,496 | 46,573 (0%) | 0% | 2.5 | 60,750 | Ordinary Shares |
| Christopher Francis | See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 May 2018 | 24,496 | 101,564 | - | - | Share Option (right to buy) | |
| Christopher Francis | See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 May 2018 | 24,496 | 77,068 | - | - | Share Option (right to buy) | |
| Christopher Francis | See Remarks | Sale of securities on an exchange or to another person at price $ 48.00 per share. | 30 May 2018 | 24,496 | 22,077 (0%) | 0% | 48 | 1,175,808 | Ordinary Shares |
| Christopher Francis | See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.48 per share. | 30 May 2018 | 24,496 | 46,573 (0%) | 0% | 2.5 | 60,750 | Ordinary Shares |
| Christopher Francis | See Remarks | Sale of securities on an exchange or to another person at price $ 45.50 per share. | 30 May 2018 | 24,496 | 22,077 (0%) | 0% | 45.5 | 1,114,568 | Ordinary Shares |
| Paul B. Bolno | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 May 2018 | 3,145 | 393,028 | - | - | Share Option (right to buy) | |
| Paul B. Bolno | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.48 per share. | 25 May 2018 | 3,145 | 282,087 (0%) | 0% | 2.5 | 7,800 | Ordinary Shares |
| Paul B. Bolno | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 45.00 per share. | 25 May 2018 | 8,316 | 278,942 (0%) | 0% | 45 | 374,220 | Ordinary Shares |
| Paul B. Bolno | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.48 per share. | 25 May 2018 | 8,316 | 287,258 (0%) | 0% | 2.5 | 20,624 | Ordinary Shares |
| Paul B. Bolno | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 45.00 per share. | 25 May 2018 | 3,145 | 278,942 (0%) | 0% | 45 | 141,525 | Ordinary Shares |
| Paul B. Bolno | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.48 per share. | 25 May 2018 | 20,250 | 299,192 (1%) | 0% | 2.5 | 50,220 | Ordinary Shares |
| Paul B. Bolno | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 45.00 per share. | 25 May 2018 | 20,250 | 278,942 (0%) | 0% | 45 | 911,250 | Ordinary Shares |
| Paul B. Bolno | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 May 2018 | 20,250 | 372,778 | - | - | Share Option (right to buy) | |
| Paul B. Bolno | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 May 2018 | 8,316 | 396,173 | - | - | Share Option (right to buy) | |
| Paul B. Bolno | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 45.00 per share. | 02 May 2018 | 18,289 | 278,942 (0%) | 0% | 45 | 823,005 | Ordinary Shares |
| Paul B. Bolno | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.48 per share. | 02 May 2018 | 18,289 | 297,231 (1%) | 0% | 2.5 | 45,357 | Ordinary Shares |
| Paul B. Bolno | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 May 2018 | 18,289 | 404,489 | - | - | Share Option (right to buy) | |
| Paul B. Bolno | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 51.62 per share. | 16 Feb 2018 | 2,200 | 278,942 (1%) | 0% | 51.6 | 113,564 | Ordinary Shares |
| Paul B. Bolno | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 51.01 per share. | 16 Feb 2018 | 514 | 281,142 (1%) | 0% | 51.0 | 26,219 | Ordinary Shares |
| Christopher Francis | See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Feb 2018 | 11,390 | 0 | - | - | Share Option (right to buy) | |
| Christopher Francis | See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Feb 2018 | 9,412 | 11,390 | - | - | Share Option (right to buy) | |
| Christopher Francis | See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Feb 2018 | 114 | 126,060 | - | - | Share Option (right to buy) | |
| Christopher Francis | See Remarks | Sale of securities on an exchange or to another person at price $ 51.80 per share. | 16 Feb 2018 | 723 | 22,077 (0%) | 0% | 51.8 | 37,451 | Ordinary Shares |
| Christopher Francis | See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.48 per share. | 16 Feb 2018 | 9,412 | 31,489 (0%) | 0% | 2.5 | 23,342 | Ordinary Shares |
| Christopher Francis | See Remarks | Sale of securities on an exchange or to another person at price $ 55.00 per share. | 16 Feb 2018 | 9,412 | 22,077 (0%) | 0% | 55 | 517,660 | Ordinary Shares |
| Christopher Francis | See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.48 per share. | 16 Feb 2018 | 11,504 | 33,581 (0%) | 0% | 2.5 | 28,530 | Ordinary Shares |
| Christopher Francis | See Remarks | Sale of securities on an exchange or to another person at price $ 55.95 per share. | 16 Feb 2018 | 11,504 | 22,077 (0%) | 0% | 56.0 | 643,649 | Ordinary Shares |
| Michael Panzara | Franchise Lead, Neurology | Sale of securities on an exchange or to another person at price $ 52.10 per share. | 16 Feb 2018 | 511 | 39,225 (0%) | 0% | 52.1 | 26,623 | Ordinary Shares |
| Keith Regnante | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 51.85 per share. | 16 Feb 2018 | 316 | 16,984 (0%) | 0% | 51.9 | 16,385 | Ordinary Shares |
| Chandra Vargeese | See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.48 per share. | 15 Feb 2018 | 2,000 | 29,300 (0%) | 0% | 2.5 | 4,960 | Ordinary Shares |
| Chandra Vargeese | See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Feb 2018 | 2,000 | 152,542 | - | - | Share Option (right to buy) | |
| Chandra Vargeese | See Remarks | Sale of securities on an exchange or to another person at price $ 50.00 per share. | 15 Feb 2018 | 2,000 | 27,300 (0%) | 0% | 50 | 100,000 | Ordinary Shares |
| Michael Panzara | Franchise Lead, Neurology | Exercise or conversion of derivative security received from the company (such as an option) at price $ 21.69 per share. | 15 Feb 2018 | 18,750 | 58,486 (0%) | 0% | 21.7 | 406,688 | Ordinary Shares |
| Michael Panzara | Franchise Lead, Neurology | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Feb 2018 | 18,750 | 131,250 | - | - | Share Option (right to buy) | |
| Michael Panzara | Franchise Lead, Neurology | Sale of securities on an exchange or to another person at price $ 50.00 per share. | 15 Feb 2018 | 18,750 | 39,736 (0%) | 0% | 50 | 937,500 | Ordinary Shares |
| Paul B. Bolno | Director, See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jan 2018 | 54,500 | 281,656 (1%) | 0% | 0 | Ordinary Shares | |
| Paul B. Bolno | Director, See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jan 2018 | 109,000 | 109,000 | - | - | Share Option (right to buy) | |
| Christopher Francis | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jan 2018 | 26,000 | 26,000 | - | - | Share Option (right to buy) | |
| Christopher Francis | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jan 2018 | 13,000 | 22,800 (0%) | 0% | 0 | Ordinary Shares | |
| Chandra Vargeese | See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Jan 2018 | 2,000 | 154,542 | - | - | Share Option (right to buy) | |
| Chandra Vargeese | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jan 2018 | 17,500 | 27,300 (0%) | 0% | 0 | Ordinary Shares | |
| Chandra Vargeese | See Remarks | Sale of securities on an exchange or to another person at price $ 40.00 per share. | 23 Jan 2018 | 2,000 | 9,800 (0%) | 0% | 40 | 80,000 | Ordinary Shares |
| Chandra Vargeese | See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.48 per share. | 23 Jan 2018 | 2,000 | 11,800 (0%) | 0% | 2.5 | 4,960 | Ordinary Shares |
| Chandra Vargeese | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jan 2018 | 35,000 | 35,000 | - | - | Share Option (right to buy) | |
| Michael Panzara | Franchise Lead, Neurology | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jan 2018 | 17,500 | 39,736 (0%) | 0% | 0 | Ordinary Shares | |
| Michael Panzara | Franchise Lead, Neurology | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jan 2018 | 35,000 | 35,000 | - | - | Share Option (right to buy) | |
| Keith Regnante | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jan 2018 | 26,000 | 26,000 | - | - | Share Option (right to buy) | |
| Keith Regnante | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jan 2018 | 13,000 | 17,300 (0%) | 0% | 0 | Ordinary Shares | |
| Gregory L. Verdine | None | Gift of securities by or to the insider at price $ 0.00 per share. | 31 Dec 2017 | 75,040 | 75,039 (0%) | 0% | 0 | Ordinary Shares | |
| Chandra Vargeese | See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Nov 2017 | 1,500 | 156,542 | - | - | Share Option (right to buy) | |
| Chandra Vargeese | See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.48 per share. | 22 Nov 2017 | 1,500 | 1,500 (0%) | 0% | 2.5 | 3,720 | Ordinary Shares |
| Chandra Vargeese | See Remarks | Sale of securities on an exchange or to another person at price $ 35.00 per share. | 22 Nov 2017 | 1,500 | 0 (0%) | 0% | 35 | 52,500 | Ordinary Shares |
| Masaharu Tanaka | Director, Ten Percent Owner | Sale of securities on an exchange or to another person at price $ 24.22 per share. | 15 Sep 2017 | 14,385 | 2,780,480 (10%) | 0% | 24.2 | 348,405 | Ordinary Shares |
| Masaharu Tanaka | Director, Ten Percent Owner | Sale of securities on an exchange or to another person at price $ 24.19 per share. | 15 Sep 2017 | 6,362 | 2,774,118 (10%) | 0% | 24.2 | 153,897 | Ordinary Shares |
| Christian O. Henry | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Aug 2017 | 9,000 | 9,000 | - | - | Share Option (right to buy) | |
| Adrian Rawcliffe | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Aug 2017 | 9,000 | 9,000 | - | - | Share Option (right to buy) | |
| Gregory L. Verdine | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Aug 2017 | 9,000 | 9,000 | - | - | Share Option (right to buy) | |
| Peter Kolchinsky | Director, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Aug 2017 | 9,000 | 9,000 | - | - | Share Option (right to buy) | |
| Koji Miura | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Aug 2017 | 9,000 | 9,000 | - | - | Share Option (right to buy) | |
| Ken Takanashi | Director, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Aug 2017 | 9,000 | 9,000 | - | - | Share Option (right to buy) | |
| Michael Panzara | Franchise Lead, Neurology | Sale of securities on an exchange or to another person at price $ 16.67 per share. | 12 Jul 2017 | 7,414 | 15,336 (0%) | 0% | 16.7 | 123,620 | Ordinary Shares |
| Masaharu Tanaka | Director, Ten Percent Owner | Sale of securities on an exchange or to another person at price $ 24.91 per share. | 29 Mar 2017 | 433,825 | 2,794,865 (11%) | 1% | 24.9 | 10,806,581 | Ordinary Shares |
| Adrian Rawcliffe | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2017 | 18,000 | 18,000 | - | - | Share Option (right to buy) | |
| Paul B. Bolno | Director, See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Jan 2017 | 72,500 | 72,500 | - | - | Share Option (right to buy) | |
| Paul B. Bolno | Director, See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Jan 2017 | 36,300 | 227,156 (0%) | 0% | 0 | Ordinary Shares | |
| Christopher Francis | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Jan 2017 | 9,800 | 9,800 (0%) | 0% | 0 | Ordinary Shares | |
| Christopher Francis | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Jan 2017 | 19,500 | 19,500 | - | - | Share Option (right to buy) | |
| Chandra Vargeese | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Jan 2017 | 9,800 | 9,800 (0%) | 0% | 0 | Ordinary Shares | |
| Chandra Vargeese | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Jan 2017 | 19,500 | 19,500 | - | - | Share Option (right to buy) | |
| Michael Panzara | Head of Neurology Franchise | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Jan 2017 | 13,800 | 13,800 | - | - | Share Option (right to buy) | |
| Michael Panzara | Head of Neurology Franchise | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Jan 2017 | 6,900 | 29,650 (0%) | 0% | 0 | Ordinary Shares | |
| Keith Regnante | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Jan 2017 | 4,300 | 4,300 (0%) | 0% | 0 | Ordinary Shares | |
| Keith Regnante | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Jan 2017 | 8,600 | 8,600 | - | - | Share Option (right to buy) | |
| Roberto Guerciolini | See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Dec 2016 | 4,000 | 4,000 | - | - | Ordinary Shares | |
| Roberto Guerciolini | See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Dec 2016 | 20,000 | 78,617 | - | - | Share Option (Right to Buy) | |
| Roberto Guerciolini | See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Dec 2016 | 20,000 | 20,000 | - | - | Ordinary Shares | |
| Roberto Guerciolini | See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Dec 2016 | 4,000 | 8,629 | - | - | Share Option (Right to Buy) | |
| Christian O. Henry | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Nov 2016 | 18,000 | 18,000 | - | - | Share Option (right to buy) | |
| Gregory L. Verdine | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Nov 2016 | 9,000 | 9,000 | - | - | Share Option (right to buy) | |
| Peter Kolchinsky | Director, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Nov 2016 | 9,000 | 9,000 | - | - | Share Option (right to buy) | |
| Koji Miura | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Nov 2016 | 9,000 | 9,000 | - | - | Share Option (right to buy) | |
| Ken Takanashi | Director, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Nov 2016 | 9,000 | 9,000 | - | - | Share Option (right to buy) | |
| Masaharu Tanaka | Director, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Nov 2016 | 9,000 | 9,000 | - | - | Share Option (right to buy) | |
| Takeshi Wada | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Nov 2016 | 9,000 | 9,000 | - | - | Share Option (right to buy) | |
| Roberto Guerciolini | See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Aug 2016 | 5,000 | 5,000 | - | - | Ordinary Shares | |
| Roberto Guerciolini | See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Aug 2016 | 5,000 | 98,617 | - | - | Share Option (Right to Buy) | |
| Keith Regnante | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Aug 2016 | 120,000 | 120,000 | - | - | Share Option (right to buy) | |
| Roberto Guerciolini | See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Jul 2016 | 5,000 | 103,617 | - | - | Share Option (Right to Buy) | |
| Roberto Guerciolini | See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Jul 2016 | 5,000 | 5,000 | - | - | Ordinary Shares | |
| Gregory L. Verdine | None | Sale of securities on an exchange or to another person at price $ 0.00 per share. | 16 Jun 2016 | 52,000 | 150,079 | - | - | Ordinary Shares | |
| Paul B. Bolno | Director, See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jun 2016 | 236,400 | 236,400 | - | - | Share Option (right to buy) | |
| Christopher Francis | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jun 2016 | 37,100 | 37,100 | - | - | Share Option (right to buy) | |
| Roberto Guerciolini | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jun 2016 | 32,500 | 32,500 | - | - | Share Option (right to buy) | |
| Kyle Moran | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jun 2016 | 30,000 | 30,000 | - | - | Share Option (right to buy) | |
| Chandra Vargeese | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jun 2016 | 49,600 | 49,600 | - | - | Share Option (right to buy) | |
| Peter Kolchinsky | Director, Ten Percent Owner | 14 Aug 2015 | 1,172,060 | 5,213,651 | - | - | Ordinary Shares | ||
| Peter Kolchinsky | Director, Ten Percent Owner | 14 Aug 2015 | 1,172,060 | 0 | - | - | Series B Preferred Shares | ||
| Peter Kolchinsky | Director, Ten Percent Owner | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 14 Aug 2015 | 1,875,000 | 7,088,651 | - | - | Ordinary Shares | |
| Peter Kolchinsky | Director, Ten Percent Owner | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 14 Aug 2015 | 1,172,060 | 1,172,060 | - | - | Series B Preferred Shares | |
| Ken Takanashi | Director, Ten Percent Owner | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 14 Aug 2015 | 161,663 | 161,663 | - | - | Series B Preferred Shares | |
| Ken Takanashi | Director, Ten Percent Owner | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 14 Aug 2015 | 125,000 | 1,984,130 | - | - | Ordinary Shares | |
| Ken Takanashi | Director, Ten Percent Owner | 14 Aug 2015 | 161,663 | 1,859,130 | - | - | Ordinary Shares | ||
| Ken Takanashi | Director, Ten Percent Owner | 14 Aug 2015 | 161,663 | 0 | - | - | Series B Preferred Shares | ||
| Masaharu Tanaka | Director, Ten Percent Owner | 14 Aug 2015 | 161,663 | 0 | - | - | Series B Preferred Shares | ||
| Masaharu Tanaka | Director, Ten Percent Owner | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 14 Aug 2015 | 161,663 | 161,663 | - | - | Series B Preferred Shares | |
| Masaharu Tanaka | Director, Ten Percent Owner | 14 Aug 2015 | 161,663 | 3,152,440 | - | - | Ordinary Shares | ||
| Masaharu Tanaka | Director, Ten Percent Owner | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 14 Aug 2015 | 76,250 | 3,228,690 | - | - | Ordinary Shares |